BIO NEWSLETTER | VC Comeback; Longevity Breakthroughs; $30B Export Target

ISSUE #25 Mar 4, 2026

📚 Browse Past Issues

WHAT WE'VE BEEN UP TO

We hosted BioHealth AI Nexus 2026 on February 25, connecting leaders across industry, academia, and institutions to share cutting-edge BioHealth × AI applications and strengthen the sector’s innovation ecosystem.

View More Photos

On February 26, the Microbiome Drug Industry Association held its 2026 Annual General Meeting and New Year Reception, reviewing last year’s achievements and plans to advance Korea’s microbiome industry.

View More Photos

WHAT'S COMING UP?

Experience the Ultimate Global Biotech Opportunities in Seoul!

EAST-WEST BIOPHARMA SUMMIT: SEOUL 2026

March 9-11, 2026

Advance Your Biotech BD Skills! (Conducted in Korean)

2026 Dealmaker Academy 1st & 2nd Seminars

April 2 & May 15, 2026

▶ Recent Events

▶ Latest News

TOP STORIES

VC Investment in Biotech Hits 4-Year High

Total venture investment in biotech and healthcare, including follow-on funding, rose 29.1% to 2.37 trillion won from 1.84 trillion won in 2023. The 534 billion won increase represented the largest growth among all sectors.

Mar 3, 2026· via [Seoul Economic Daily]

Virtual cells and anti-aging therapies named key future biotechnologies

Simulating entire cells with artificial intelligence (AI) and rejuvenating old cells with a single application of RNA.

Feb 26, 2026· via [DongA Science]

Korea lifts biohealth exports to record $27.9B, targets $30.4B next

The ministry set the 2026 export target at $30.4 billion, up 9.1% from the previous year.

Mar 3, 2026· via [ChosunBiz]

Here's what's happening across Korea's bio industry!

INSIDE KOREA BIO

🚀 Goes Global

∎ Global leaders, who will draw a new topographic map of the pharmaceutical and bio industries around the world, are ready to go to Seoul - Maeil Business Newspaper

∎ Korean pharma expands in Vietnam, Brazil and India to diversify growth - ChosunBiz
∎ Korea Links Songdo and Tokyo to Build a Cross-Border Startup Pipeline in Bio and AI - KoreaTechDesk
∎ GC Cell registers core platform technology patents for next-generation cell and gene therapies in Korea and Japan - THE BIO
∎ Ministry of Health and Welfare Signs 710 Billion Won Investment MOU with Roche - The Asia Business Daily

📈 Growth & Performance

∎ ABL209 Receives FDA Approval: What This Dual Antibody ADC Means for Cancer Treatment - News1

∎ Daewoong Pharmaceutical targets global obesity market with pain-free microneedle patch - THE BIO

∎ From petflation to pharma gold rush: Korea’s booming pet healthcare market - KBR

∎ In Vivo CAR-T Therapy Promises Single Injection Cancer Treatment - The Chosun Ilbo

∎ SK bioscience, IDT Biologika and Vaxxas Selected for Next-Generation Influenza Vaccine development Financed by the European Union - BioSpace
∎ Korean Drugmakers Expand Into Senior Care as Super-Aged Society Grows - Aju Press
∎ Korean Firms Develop Topical, Injectable Hair Loss Treatments - The Chosun Ilbo

💡 Innovation & Trends

∎ AI Model Predicts Glaucoma Risk After Vitrectomy Surgery - Seoul Economic Daily
∎ As Korea’s AI Basic Act Takes Effect, DeepBrain AI Moves Deepfake Detection into Global Infrastructure - KoreaTechDesk
∎ First Step Toward National Strategy for Synthetic Biology... Government Launches Formulation of the 1st Promotion Master Plan - The Asia Business Daily
∎ Gene-Modified Rice Cuts Methane Emissions by 24% - Seoul Economic Daily
∎ GI Innovation launches ‘K-Bio Innovation’ initiative as the KRW 45 trillion Keytruda ecosystem takes center stage - THE BIO
∎ South Korea Faces Crucial Moment in Medical AI Adoption - Business Korea

Join our press list

Get KoreaBIO updates
& media resources

Share Your thoughts!

How was your letter today?

Korean Newsletter

Daily biotech news from Korea and around the world
— in Korean

Stay connected with everything

Watch and Join!

KoreaBIO (Korea Biotechnology Industry Organization)
700 Daewangpangyo-ro, Bundang-gu, Seongnam-si, Gyeonggi-do, Republic of Korea

+82-31-628-0037
수신거부 Unsubscribe